-

InterVenn Biosciences to Participate at Two Upcoming Investor Conferences in November

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--InterVenn Biosciences today announced that company management will participate at the following virtual investor conferences:

  • Stifel 2021 Virtual Healthcare Conference
    Formal presentation on Tuesday, November 16, 2021 at 11:00 a.m. PT / 2:00 p.m. ET
  • Canaccord Genuity Virtual MedTech, Diagnostics, and Digital Health & Services Forum
    Fireside chat on Thursday, November 18, 2021 at 1:00 p.m. PT / 4:00 p.m. ET

A live webcast of the Stifel event will be available on the “For Investors” section of the InterVenn website at https://intervenn.com/investors/ and will be available for 90 days thereafter.

About InterVenn Biosciences

InterVenn Biosciences utilizes a proprietary glycoproteomic biomarker interrogation platform using AI and mass spectrometry for next-gen precision medicine. The company is working to find new solutions in ovarian, pancreatic, liver, prostate, and kidney cancer, together with applications from the PerspectIV™ suite of solutions for treatment and monitoring, immune profiling, patient stratification, and disease progression. For more information about InterVenn Biosciences, please visit the company’s website.

Contacts

Andrea Vuturo
press@venn.bio
(888) 706-1670

Industry:

InterVenn Biosciences

Details
Headquarters: South San Francisco, California
CEO: Andrew Quong, Ph.D.
Employees: 0-100
Organization: PRI
Release Summary
InterVenn Biosciences announces their participation in investor conferences: Stifel 2021 Healthcare Conference and Canaccord Genuity Virtual Forum.
Release Versions
English
Hashtags
#AI
#AIML
#MSLC
#artificialintelligence
#biomarker
#biomarkerdiscovery
#biomarkers
#cancer
#cancerresearch
#conference
#datascience
#forum
#glycoproteomics
#health
#intervenn
#investorconference
#investors
#massspec
#proteomics
#vennbio
#virtualconference

Contacts

Andrea Vuturo
press@venn.bio
(888) 706-1670

Social Media Profiles
InterVenn on Facebook
InterVenn on LinkedIn
More News From InterVenn Biosciences

InterVenn Presents Results Detailing Glycoproteomic Signature Predictive of Response to Immune Checkpoint Inhibitor Treatment in Advanced Non-Small Cell Lung Cancer at American Society for Immunotherapy of Cancer

WASHINGTON--(BUSINESS WIRE)--InterVenn presents results at SITC on a predictive signature capable of identifying NSCLC patients that will benefit most from checkpoint inhibitors...

InterVenn Presents Results at American Society for Mass Spectrometry Conference Demonstrating that Differential Peripheral Blood Glycoproteomic Signatures are Associated with Symptomatic vs. Asymptomatic Course of COVID-19 Infection

PHILADELPHIA--(BUSINESS WIRE)--InterVenn Biosciences presented results today on the application of its perspectIV™ platform in COVID-19 patients....

InterVenn Biosciences to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--InterVenn Biosciences announces that it will be participating via webcast in the Morgan Stanley 19th Annual Global Healthcare Conference....
Back to Newsroom